Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...
Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; ...
As the stadium showdown continues, Ronayne will address the dome stadium proposal from the Browns later Wednesday afternoon.
Eugene "Big U" Henley, considered a fugitive, portrayed himself as an anti-gang activist associated with a charity that ...
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the ...
A disciplinary panel on Monday night declined to strip Clark County Commissioner Justin Jones’ law license, an action the ...
The results of COMP004 build upon previous findings from the Phase 2b trial COMP001, which showed that a single 25mg dose of COMP360 psilocybin was associated with a rapid and highly statistically ...
Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status SAN DIEGO, March 1 ...
In November 2024, Zealand Pharma presented detailed results from the Phase 1b 16-week multiple ascending dose (MAD) trial at ...
A business bank statement tracks transactions, balances, and cash flow. Learn key components and tips for better financial ...
Fourth Quarter and Full Year 2024 Financial Results: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback